Search research articles
Contact Us
Filters
Showing results (1-10 of 451) with videos related to
Page
of 46
Sort By:
Rhode Island Medical Journal (2013)
|
August 2, 2021
SARS-CoV-2 Variants and their Clinical Implications
Eleftherios Mylonakis
Current Pharmaceutical Design
|
April 8, 2011
The need to redefine antimicrobial drug discovery
Eleftherios Mylonakis
Rhode Island Medical Journal (2013)
|
July 14, 2022
SARS-CoV-2 Variants and Their Clinical Significance: An Update as of May 2022
Eleftherios Mylonakis
Mycopathologia
|
December 7, 2007
Galleria mellonella and the study of fungal pathogenesis: making the case for another genetically tractable model host
Eleftherios Mylonakis
Infection and Immunity
|
June 24, 2005
Worms and flies as genetically tractable animal models to study host-pathogen interactions
Eleftherios Mylonakis, Alejandro Aballay
Infection and Immunity
|
May 16, 2012
Caenorhabditis elegans immune conditioning with the probiotic bacterium Lactobacillus acidophilus strain NCFM enhances gram-positive immune responses
Younghoon Kim, Eleftherios Mylonakis
Cell Reports
|
September 7, 2017
An Intestine-Derived Neuropeptide Controls Avoidance Behavior in Caenorhabditis elegans
Kiho Lee, Eleftherios Mylonakis
Virulence
|
December 17, 2014
Effector triggered immunity
Rajmohan Rajamuthiah, Eleftherios Mylonakis
Expert Opinion on Drug Discovery
|
January 16, 2026
Advances in methicillin-resistant <i>staphylococcus aureus</i> drug discovery: developments and challenges
Stephanos Vassilopoulos, Eleftherios Mylonakis
Annals of Internal Medicine
|
May 19, 2020
In utero exposure to systemic antibiotics vs reference penicillins was not linked to congenital malformations
Eleftheria Atalla, Eleftherios Mylonakis
Page
of 46
Search research articles
Search
Showing results (1-10 of 451) with videos related to
Sort By:
Page
of 46
Rhode Island Medical Journal (2013)
|
August 2, 2021
SARS-CoV-2 Variants and their Clinical Implications
Eleftherios Mylonakis
Current Pharmaceutical Design
|
April 8, 2011
The need to redefine antimicrobial drug discovery
Eleftherios Mylonakis
Rhode Island Medical Journal (2013)
|
July 14, 2022
SARS-CoV-2 Variants and Their Clinical Significance: An Update as of May 2022
Eleftherios Mylonakis
Mycopathologia
|
December 7, 2007
Galleria mellonella and the study of fungal pathogenesis: making the case for another genetically tractable model host
Eleftherios Mylonakis
Infection and Immunity
|
June 24, 2005
Worms and flies as genetically tractable animal models to study host-pathogen interactions
Eleftherios Mylonakis, Alejandro Aballay
Infection and Immunity
|
May 16, 2012
Caenorhabditis elegans immune conditioning with the probiotic bacterium Lactobacillus acidophilus strain NCFM enhances gram-positive immune responses
Younghoon Kim, Eleftherios Mylonakis
Cell Reports
|
September 7, 2017
An Intestine-Derived Neuropeptide Controls Avoidance Behavior in Caenorhabditis elegans
Kiho Lee, Eleftherios Mylonakis
Virulence
|
December 17, 2014
Effector triggered immunity
Rajmohan Rajamuthiah, Eleftherios Mylonakis
Expert Opinion on Drug Discovery
|
January 16, 2026
Advances in methicillin-resistant <i>staphylococcus aureus</i> drug discovery: developments and challenges
Stephanos Vassilopoulos, Eleftherios Mylonakis
Annals of Internal Medicine
|
May 19, 2020
In utero exposure to systemic antibiotics vs reference penicillins was not linked to congenital malformations
Eleftheria Atalla, Eleftherios Mylonakis
Page
of 46